APUSHealthcare · Drug Manufacturers - Specialty & Generic

APUS Stock Forecast: Apimeds Pharmaceuticals US, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$2.11

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap

$3.2M

Ticker Nerd rank

9 / 100

Median analyst target

—

Analysts covering

—

Revenue$0.0

Operating income−$6.3M

Net income−$20.2M

Free cash flow−$5.7M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Ticker Nerd rank

APUS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Apimeds Pharmaceuticals US, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

9 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Volatility

Quality

Revisions

Value

Issuance

Growth

Momentum

Size (98): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

APUS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APUS, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APUS appears on the weeks it earns a place.

Estimates

APUS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Apimeds Pharmaceuticals US, Inc. (APUS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.4×
Price / sales: —
Price / book: 3.2×
EV / EBITDA: −0.8×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −3.9%
Return on assets: −3.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Apimeds Pharmaceuticals US, Inc. (APUS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Apimeds Pharmaceuticals US, Inc. has a market value of $3.2M and an enterprise value of $9.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$58.2M.
Free cash flow in the twelve months to 30 June 2026: −$13.3M.
Shares outstanding: 150,911.
Trailing P/E: −0.4×.
Apimeds Pharmaceuticals US, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

APUS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
APUSApimeds Pharmaceuticals US, Inc.	$3.2M	9
SXTCChina Sxt Pharmaceuticals, Inc.	$3.4M	11
PRFXPRF Technologies Ltd.	$2.6M	4
SBFMSunshine Biopharma, Inc.	$4.1M	61
BTAIBioXcel Therapeutics, Inc.	$2.3M	—
SHPHShuttle Pharmaceuticals Holdings, Inc.	$2.2M	16
YCBDcbdMD, Inc.	$5.4M	28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Apimeds Pharmaceuticals US, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APUS news & analysis

NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange

GlobeNewsWire · 3 Aug 2026positive

MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (APUS), announced that its NILA token is now available to eligible U.S. users on Webot, a licensed U.S. cryptocurrency exchange. This marks the first time eligible U.S. users can access NILA through a licensed American platform.

Why it matters — APUS watchers would care because its subsidiary's NILA token has gained its first availability to eligible U.S. users on a licensed American cryptocurrency exchange, expanding the token's U.S. market access.

MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October

GlobeNewsWire · 28 July 2026positive

MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (APUS), announced MindChain, described as the world's first fully insured blockchain. It is an insured, production-grade, EVM-compatible Layer 2 network that will launch in October 2026.

Why it matters — APUS shareholders may be interested because a subsidiary is launching a novel blockchain product, potentially expanding the company's business beyond pharmaceuticals.

FAQ

Frequently asked questions about APUS stock

How does Ticker Nerd's model rank APUS?

As at 12 Sept 2026, Apimeds Pharmaceuticals US, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the APUS stock forecast for 2030?

No analyst covering Apimeds Pharmaceuticals US, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APUS are extrapolating price history, which says nothing about the business.

What does Apimeds Pharmaceuticals US, Inc. do?

Apimeds Pharmaceuticals US Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, a purified bee venom-based therapeutic candidate delivered intradermally.

What is the latest news on APUS?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange". MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (APUS), announced that its NILA token is now available to eligible U.S. users on Webot, a licensed U.S. cryptocurrency exchange. This marks the first time eligible U.S. users can access NILA through a licensed American platform.

Company

About Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, a purified bee venom-based therapeutic candidate delivered intradermally. The company is primarily working on treatments for inflammation and pain management, with an emphasis on knee osteoarthritis and, to a lesser extent, multiple sclerosis. Its current business centers on advancing this non-narcotic drug candidate through clinical development and related pharmaceutical activities. Apimeds Pharmaceuticals US Inc. also operates as part of a broader biopharmaceutical platform that includes research, development, and potential commercialization capabilities. Headquartered in Matawan, New Jersey, the company is positioned within the specialty drug manufacturing and biotechnology markets, where its work targets high-need conditions in musculoskeletal and inflammatory care.

CEO Dr. Vinod Menon · 2 employees · United States · https://www.mindwavedao.com